SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q2 2025 vs. Q1 2025
How the institutions holding SAB Biotherapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 26 | 25 | −1 |
| Shares | 2.21M | 1.92M | −285.7K (−12.9%) |
| Value | $2.99M | $3.37M | +$375.1K (+12.5%) |
New holders (3)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 17,095 | $29.9K | 0.00% |
| Creative Planning | 11,852 | $20.8K | 0.00% |
| Raymond James Financial Inc | 45 | $79 | 0.00% |
Sold out (4)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| HB Wealth Management, LLC | 263,200 | $358.0K |
| Silver Oak Securities, Inc | 20,188 | $29.9K |
| XTX Topco Ltd | 16,555 | $22.3K |
| Millennium Management LLC | 16,351 | $22.1K |